| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Gynecologic Oncology |
aNational Cancer Institute, Bethesda, Maryland, USA; bJohns Hopkins Hospital, Baltimore, Maryland, USA
Correspondence: Correspondence: Edward L. Trimble, M.D., M.P.H., Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard, Suite 7025, MSC 7436, Bethesda, Maryland 20892-7436, USA. Telephone: 301-496-2522; Fax: 301-402-0557; e-mail: trimblet{at}ctep.nci.nih.gov
Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.
In 2006, i.p. chemotherapy re-emerged as a controversial topic in debates about the optimal treatment for women with advanced epithelial ovarian cancer. In this paper, we address the rationale behind i.p. chemotherapy, the data supporting its use, the selection of appropriate patients for i.p. chemotherapy, how best to avoid and manage the toxicities observed with i.p. chemotherapy, and directions for future research.
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |